NASDAQ:VLON

Vallon Pharmaceuticals (VLON) Stock Forecast, Price & News

$5.59

-0.20 (-3.45%)

(As of 05/30/2023 ET)

Compare

Today's Range: $5.59
▼
$6.10
50-Day Range: $5.59
▼
$16.17
52-Week Range: $0.21
▼
$12.92

Volume: 6,402 shs
Average Volume: 5.78 million shs
Market Capitalization: $75.36 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Vallon Pharmaceuticals (NASDAQ:VLON) Stock

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

Receive VLON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vallon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VLON Stock News Headlines

April 22, 2023 | americanbankingnews.com

Vallon Pharmaceuticals Stock to Reverse Split on Monday, April 24th (NASDAQ:VLON)

April 20, 2023 | bizjournals.com

Vallon Pharmaceuticals' shareholders approve reverse merger with California company

May 31, 2023 | Behind the Markets (Ad)

⚡ 2,467% Return on Israeli Laser Company?

This advanced laser system is active in 80 countries around the world. And at the center of this massive market is a small firm in Israel. Our research shows that anyone who gets in today could see a return of 2,467%. But that's only if the company doesn't get taken over for a fast 300% gain first.

April 20, 2023 | finance.yahoo.com

Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split

April 12, 2023 | finance.yahoo.com

Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023

April 7, 2023 | bizjournals.com

Lab Notes: CHOP gets $10M research gift; Vallon seeks greater shareholder support for merger

April 4, 2023 | finance.yahoo.com

Vallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ET

March 28, 2023 | americanbankingnews.com

Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) Short Interest Down 80.1% in March

May 31, 2023 | Behind the Markets (Ad)

⚡ 2,467% Return on Israeli Laser Company?

February 24, 2023 | finanznachrichten.de

Vallon Pharmaceuticals Inc.: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results

February 24, 2023 | finance.yahoo.com

Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results

February 14, 2023 | benzinga.com

Is Vallon Pharmaceuticals Inc (VLON) recent surge justified

January 11, 2023 | finance.yahoo.com

Vallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Event

December 27, 2022 | benzinga.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vallon Pharmaceuticals, Inc. - VLON

December 14, 2022 | bizjournals.com

Vallon Pharmaceuticals to merge with California biotech firm in 'best path forward'

December 14, 2022 | msn.com

What's Going On With Vallon Pharmaceuticals Stock Today?

December 14, 2022 | benzinga.com

Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket

December 13, 2022 | finance.yahoo.com

Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators

November 3, 2022 | finance.yahoo.com

Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results

July 28, 2022 | finance.yahoo.com

Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

July 20, 2022 | finance.yahoo.com

Vallon Pharmaceuticals, Inc. (VLON)

May 16, 2022 | bizjournals.com

Vallon Pharmaceuticals plans $3.9M stock sale to support exploration of strategic alternatives

May 13, 2022 | seekingalpha.com

Vallon Pharmaceuticals to raise $3.9M in stock offering

May 13, 2022 | finance.yahoo.com

Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering

May 12, 2022 | finance.yahoo.com

Vallon Pharma Posts Additional Data From SEAL Study Of Formulated CNS Stimulant

May 12, 2022 | finance.yahoo.com

Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR

May 11, 2022 | finance.yahoo.com

Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufacturing for ADAIR

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VLON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vallon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VLON Company Calendar

Today: 5/31/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VLON
CUSIP: N/A
CIK: 1824293
Web: www.vallon-pharma.com
Phone: 267-607-8255
Fax: N/A
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.78)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,020,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -230.48%
Return on Assets: -124.89%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.29
Quick Ratio: 2.29

Sales & Book Value

Annual Sales: $100,000.00
Price / Sales: 753.64
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.18 per share
Price / Book: 31.06

Miscellaneous

Outstanding Shares: 13,482,000
Free Float: 8,453,000
Market Cap: $75.36 million
Optionable: Not Optionable
Beta: -1.14

Key Executives

Mr. David C. Baker (Age 59)
CEO, Pres & Director
Comp: $553.55k

Ms. Leanne M. Kelly (Age 45)
Chief Financial Officer
Comp: $328.52k

Dr. Ofir Levi Ph.D. (Age 48)
Consulting

Dr. Timothy M. Whitaker (Age 63)
Chief Medical Officer

Key Competitors

View All Competitors

VLON Stock - Frequently Asked Questions

How have VLON shares performed in 2023?: Vallon Pharmaceuticals' stock was trading at $8.70 at the start of the year. Since then, VLON stock has decreased by 35.7% and is now trading at $5.59.
View the best growth stocks for 2023 here.
When did Vallon Pharmaceuticals' stock split?: Vallon Pharmaceuticals's stock reverse split before market open on Monday, April 24th 2023. The 1-30 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
When did Vallon Pharmaceuticals IPO?: (VLON) raised $15 million in an initial public offering on Wednesday, February 10th 2021. The company issued 1,700,000 shares at a price of $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.
What is Vallon Pharmaceuticals' stock symbol?: Vallon Pharmaceuticals trades on the NASDAQ under the ticker symbol "VLON."

How do I buy shares of Vallon Pharmaceuticals?: Shares of VLON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vallon Pharmaceuticals' stock price today?: One share of VLON stock can currently be purchased for approximately $5.59.
How much money does Vallon Pharmaceuticals make?: Vallon Pharmaceuticals (NASDAQ:VLON) has a market capitalization of $75.36 million and generates $100,000.00 in revenue each year. The company earns $-7,020,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.
How can I contact Vallon Pharmaceuticals?: Vallon Pharmaceuticals' mailing address is TWO LOGAN SQUARE 100 N. 18TH STREET SUITE 300, PHILADELPHIA PA, 19103. The official website for the company is www.vallon-pharma.com. The company can be reached via phone at 267-607-8255 or via email at vallon@jtcir.com.

This page (NASDAQ:VLON) was last updated on 5/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial